BioCryst and Presidio Merge to Compete in Oral Hepatitis C Drug Development
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 8 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1831 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to compete in the race to develop an all-oral treatment regimen for chronic hepatitis C virus (HCV) infection, BioCryst Pharmaceuticals has agreed to acquire Presidio Pharmaceuticals in an all-stock merger agreement...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS